Roberto Carmagnani Pestana

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

R. Carmagnani Pestana, R. Pestana, R.C. Pestana, Rebeca Pestana, Roberto C. Pestana, Roberto Carmagnani Pestana, Roberto Carmagnani Pestana, Roberto Pestana, Roberto Carmagnani Pestana

121

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Sarah Cannon Hospital Israelita Albert Einstein Rutgers Cancer Institute Rutgers, The State University of New Jersey

About

Roberto Carmagnani Pestana is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	407
2	Health Sciences	3	3	155
3	Public Health	1	1	15
4	Cell Biology	1	1	133
5	Epidemiology	1	1	15

Roberto Carmagnani Pestana

Publications

763

Citations

H-Index

Page 1

	Year	Citations
IL-6–Mediated Induction of Matrix Metalloproteinase-9 Is Modulated by JAK-Dependent IL-10 Expression in Macrophages Poonam Kothari, Roberto Carmagnani Pestana, Rim Mesraoua, The Journal of Immunology Pge2 SynthesisImmunologyImmune RegulationImmunologic MechanismInnate Immunity	2013	133
Moving Beyond 3+3: The Future of Clinical Trial Design Razelle Kurzrock, Chia‐Chi Lin, Tsung‐Che Wu, American Society of Clinical Oncology Educational Book Patient SelectionBeyond 3+3ImmunologyImmunotherapyMetronomic Therapy	2021	102
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA Ahmed O. Kaseb, Nora Sánchez, Shiraj Sen, Clinical Cancer Research	2019	76
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma Ahmed O. Kaseb, Luis M. Vence, Jorge Blando, Cancer Immunology Research	2019	67
Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases Amanda Parkes, Carla L. Warneke, Katherine Clifton, The Oncologist	2018	65
Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma Roberto Carmagnani Pestana, Melody Becnel, Maria Laura Rubin, Oral Oncology Neoadjuvant TherapyMedicineImmunologyImmune Checkpoint InhibitorRecurrent/metastatic Head	2019	61
Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC Aliya Qayyum, Ken‐Pin Hwang, Jason Stafford, Journal for ImmunoTherapy of Cancer	2019	50
Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets Jason Roszik, Abir Khan, Anthony P. Conley, Cancers	2019	32
Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. Ahmed O. Kaseb, Dan G. Duda, Hop Sanderson Tran Cao, Journal of Clinical Oncology Surgical OncologyClinical EndpointImmunologyImmunoeditingPharmacotherapy	2020	28
Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC. Ahmed O. Kaseb, Roberto Carmagnani Pestana, Luis M. Vence, Journal of Clinical Oncology Surgical OncologyClinical EndpointImmunologyImmunoeditingPharmacotherapy	2019	25

Page 1